Chinese Pharma Innovation Flourishes: Hansoh Partners with Regeneron, Luye's Zepzelca Shows Breakthrough Efficacy, and Takeda China Launches New ST2 Antibody Trial

6Month2On [date], Hansoh Pharma announced that it had entered into a licensing agreement with Regeneron, granting the latter the rights to develop, manufacture, and commercializeHS-20094The global exclusive license (excluding mainland China, Hong Kong, and Macao) rights.

According to the agreement, Hansoh Pharma will obtain8000Million US dollars as the upfront payment, and is eligible to receive up to a maximum amount based on the product's development, regulatory approval, and commercialization progress.19.3USD billion milestone payments, as well as double-digit percentage royalties on potential future product sales.

HS-20094is a research and developmentGLP-1/GIPDual Receptor Agonist, Has Successfully Completed MultiplePhase IIClinical trials, with positive efficacy and safety data, are currently being conducted in China.Phase ⅢClinical trial.

Currently, the only one in the world is Tirzepatide.GLP-1R/GIPRAgonist launched. Enterprises in ChinaGLP-1R/GIPRThe follow-up speed of the track is relatively fast, and globally it is inPhase IIIStageGLP-1R/GIPRAgonists almost all come from pharmaceutical companies in China, including BrightGene.、Hengrui Medicine、Z众生睿创etc.。

Local time6Month2Day,Jazz PharmaceuticalsPublication of Lurbinectedin+TecentriqLatest Phase III Clinical Data for First-Line Treatment of Small Cell Lung Cancer (SCLC). Lurbinectedin+TecentriqCombined Therapy Group andTecentriqMonotherapy group,mPFSRespectively5.4Months,2.1Months,HR=0.54，p＜0.0001，mOSRespectively13.2Months,10.6Months,HR=0.73，p=0.0174`, the risk of disease progression or death was reduced`46%`, Risk of death reduced`27%。

2020Year6In the month, Lurbinectedin was approved for second-line treatment.SCLC, the marketing application for first-line treatment has been submitted.ZepzelcaFrom2020Since its approval for marketing in [Year], the cumulative sales have exceeded10Billion US dollars,2023Annual Sales2.90Billion US dollars,2024Annual Sales3.20Billion US dollars.

It is reported that,Lurbinectedin was initially developed byPharmaMarResearch and Development,2019Year4In the month, Luye Pharma acquired the China rights to Lurbinectedin,2019Year12Month,Jazz PharmaceuticalsIntroduce the overseas rights of Lurbinectedin.2024Year12In the month, Lurbinectedin was approved for marketing in China.

5 Month30 The other day, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that CHIATAI TIANQING registered a...ST2 Monoclonal AntibodyTQC2938 Combined Background Therapy in Seasonal Allergic Rhinitis (SAR) Phase II Clinical Trial on the Efficacy and Safety in Patients (Registration No.:CTR20252117）。

It is reported that this is a randomized, double-blind, placebo-controlled, multi-center,Phase II Clinical Study, Aiming to EvaluateTQC2938Injection Combined with Background Therapy inSAREfficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity in patients, while exploring the drug'sSARRole of Subgroups of Patients with Comorbid Asthma and Related Efficacy Biomarkers.

Public data shows,TQC2938Yu2022Year4Applied for clinical trials in China for the first time in the same year6Approved for clinical use in China in the treatment of moderate to severe asthma in [Month],23Year3First public clinical trial in the month, targeting asthma and chronic obstructive pulmonary diseaseCOPD。

It is understood that,TQC2938 Is a treatment forST2HumanizationIgG2Monoclonal antibodies, capable of reducing downstreamTh2Production of cytokines, reducing the levels of inflammatory cells. Preclinical animal efficacy experiments show that the drug can significantly improve disease symptoms. Currently, there are only a few such drugs available globally.ST2Monoclonal antibodies under research, respectively from Amgen/Roche, CHIATAI TIANQING, Johnson & Johnson, Mabwell.